I'm happy to.
I think our work is supporting biotechnology companies that are bringing these important medicines to patients, or trying to. A number of them have gone bankrupt. They have raised hundreds of millions of dollars, approaching $1 billion, and brought the drug through successful clinical trials into approval, only to go bankrupt because they couldn't afford to keep the lights on after the drug was approved. That's how difficult this market is. That's how challenging it is.
We're not even talking about what it costs to then expand into other jurisdictions. To get approval in the U.S., maybe a first step to then getting approval in Canada and to getting approval in other jurisdictions, is absolutely necessary to bring it to patients where the need is, yet the companies don't have the resources to do that.
This has become so challenging that other investors simply refuse to consider investing in this field any more. We've heard that large pharmaceutical companies have left the field, and that has created a whole series of challenges in supporting innovation here.
All those things conspire to keep these needed drugs out of the innovation pipeline and unavailable to patients around the world. If we don't create these pull incentives so there's a market to keep the drugs available once they've been approved, there simply won't be any more coming.